Chimeric antigen receptor (CAR) T cell therapy targeting CA19-9, an antigen over-expressed in several cancers, including 80-90% of pancreatic cancers.
A method to combine two or three monoclonal antibodies (mABs) into one treatment to successfully bind to multiple cancer cell surface epitopes and promote targeted degradation by phagocytosis.
Synergistic combination of mechanoporation and lipid nanoparticle (LNP) based transfection for an efficient, non-viral method of gene transfer to generate CAR-T cell therapies.
A Switchable Bispecific T-Cell Nanoengager (sBiTNE) to link T cells with cancer cells that can be reversed if off-tumor toxicity is detected.
A method to inhibit small extracellular vesicles (sEVs) released by tumor cells to enhance lipid nanoparticle (LNP) accumulation in tumors.
Intranasal nasal dantrolene nanoparticles alone, or in combination with lithium, can provide protection against depression and dementia with minimal or no side effects.
A method to streamline the process of generating chimeric antigen receptor (CAR) T cells for therapeutic applications.
CAR-T cells are PEGylated to block the interactions with monocytes and macrophages to reduce the side effects of CAR-T cell therapies (cytokine release syndrome and neurotoxicity).
Researchers developed an LNP-mRNA-based vaccine that encodes different cytokine mRNAs, as a method to enhance CD8+ T cell responses and memory formation.
Topical LSD1 inhibition can treat skin diseases that include cutaneous squamous cell carcinoma (cSCC), actinic keratoses, and viral warts.